Skip to main content

Table 1 Summary of efficacy and safety assessments carried out throughout the study

From: Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study

 

Treatment period (weeks)

Post-treatment period (weeks)

 

SD1

2

6

10

14

18

22

26

34

42

52

4

Efficacy and safety assessments*

 

X

X

X

X

X

X

X

X

X

X

X

IBDQ assessment

X

      

X

  

X

 

CDAI assessment

X

X

X

X

X

X

X

X

X

X

X

 

CRP

X

 

X

 

X

 

X

X

X

X

X

X

ESR

X

 

X

 

X

 

X

X

X

X

X

X

Antibodies to IFN beta-1a

X

      

X

  

X

 

Thyroid function

X

      

X

  

X

 

Urinalysis

X

      

X

  

X

X

Pregnancy testing

X

  

X

 

X

 

X

  

X

 
  1. CDAI: Crohn's disease activity index; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; IBDQ: inflammatory bowel disease questionnaire; IFN, interferon; SD1, study day 1
  2. *Safety data were obtained by monitoring adverse events/serious adverse events, concomitant medications, physical examinations, vital signs and routine analysis of blood (haematology and chemistry)